Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia.

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Vascular Biology

Background:

• Mildly elevated plasma homocysteine is an independent risk factor for atherothrombotic vascular disease.
• Hyperhomocysteinemia contributes to vascular disorders through endothelial dysfunction, including impaired vasoregulation and antithrombotic function.
• Homocysteine-induced oxidant stress reduces nitric oxide bioavailability, central to endothelial dysfunction.

Purpose of the Study:

• To investigate the role of homocysteine in atherothrombotic vascular disease.
• To explore the mechanisms of homocysteine-induced endothelial dysfunction.
• To evaluate the efficacy of folic acid and vitamin B12 supplementation in managing hyperhomocysteinemia and its vascular effects.

Main Methods:

• Review of existing literature on homocysteine and vascular disease.
• Analysis of molecular mechanisms linking homocysteine to endothelial dysfunction, including oxidant stress and nitric oxide pathways.
• Examination of studies on folic acid and vitamin B12 supplementation for homocysteine reduction and endothelial function improvement.

Main Results:

• Elevated homocysteine impairs endothelial function by increasing oxidant stress and decreasing nitric oxide bioavailability.
• Supplementation with folic acid and vitamin B12 effectively lowers plasma homocysteine levels.
• These supplements can reverse homocysteine-induced impairments in endothelium-dependent vasoreactivity.

Conclusions:

• Hyperhomocysteinemia contributes to atherothrombotic vascular disease via endothelial dysfunction.
• Folic acid and vitamin B12 supplementation show promise in mitigating these vascular risks.
• Further intervention trials are needed to confirm the role of homocysteine-lowering therapies in preventing atherothrombotic events.